Peer-reviewed study confirms every major pharma company ran systematic bribery schemes for 20+ years — $1.1 billion in sanctions

Every Major Pharma Company Was Running Bribery Schemes. A 20-Year Study Just Proved It.

A peer-reviewed study published in the Journal of Law, Medicine & Ethics analyzed 20 years of OECD enforcement data and found something the industry has spent billions trying to hide: every major pharmaceutical company was systematically bribing officials through shell companies and subsidiaries.

Who's Named

Pfizer. Johnson & Johnson. Eli Lilly. Bristol-Myers Squibb. AstraZeneca. GlaxoSmithKline. Not some of them — all of them. The University of Toronto research team found documented bribery across every major pharmaceutical corporation operating internationally.

How They Did It

Shell companies. Subsidiaries with no obvious connection to the parent corporation. Third-party "consultants" who were really bagmen. The study documented a systematic pattern where pharma companies created layers of corporate separation to distance themselves from the bribes their money was paying.

$1.1 Billion in Sanctions

Despite the scale of the bribery, total sanctions across 20 years amounted to $1.1 billion — a rounding error for companies generating hundreds of billions in annual revenue. The fines were cost of doing business, and the companies knew it.

Internal Warnings Ignored

The study found evidence that internal compliance teams at multiple companies flagged suspicious payments and practices. Those warnings were documented. And ignored. The companies didn't fail to catch the bribery — they chose to continue it.